An asymmetric split-costimulatory MSLN.BBz/NKG2D.28 dual CAR-T design enhances activity against antigenically heterogeneous pancreatic cancer
Molecular Therapy: Oncology
· Elsevier
The publisher did not provide an abstract — full text is available via the link below.
Read at publisher →
Citation
An asymmetric split-costimulatory MSLN.BBz/NKG2D.28 dual CAR-T design enhances activity against antigenically heterogeneous pancreatic cancer. // Molecular Therapy: Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2950329926002250?dgcid=rss_sd_all
An asymmetric split-costimulatory MSLN.BBz/NKG2D.28 dual CAR-T design enhances activity against antigenically heterogeneous pancreatic cancer. Molecular Therapy: Oncology. https://www.sciencedirect.com/science/article/pii/S2950329926002250?dgcid=rss_sd_all
“An asymmetric split-costimulatory MSLN.BBz/NKG2D.28 dual CAR-T design enhances activity against antigenically heterogeneous pancreatic cancer.” Molecular Therapy: Oncology.
@article{article59098,
title = {An asymmetric split-costimulatory MSLN.BBz/NKG2D.28 dual CAR-T design enhances activity against antigenically heterogeneous pancreatic cancer},
journal = {Molecular Therapy: Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2950329926002250?dgcid=rss_sd_all}
}